In this interview, we dive into Moderna’s evolving strategy with Francesca Ceddia, the Chief Medical Affairs Officer of Moderna. By using its mRNA platform to go beyond COVID-19 and build a future-facing pipeline. You’ll learn how Moderna is developing cancer therapies (including personalized cancer vaccines), its FDA‑approved RSV vaccine (mRESVIA), and mRNA treatments for rare metabolic diseases like propionic acidemia and methylmalonic acidemia. We also break down how lipid nanoparticle delivery enables repeated dosing and better safety — all part of Moderna’s ambition to transform medicine with flexible, scalable mRNA technology.
Read the full article here: https://www.geneonline.com/modernas-next-act-how-mrna-platform-is-tackling-cancer-rsv-and-rare-diseases/
